Clinical Trial Update: Evaluate Efficacy, Safety and Tolerability of JTT-861 in Subjects With Heart Failure With Reduced Ejection Fraction [Phase 2]

View source ↗

Summary

A Phase 2 trial update reports ongoing evaluation of JTT-861 for efficacy, safety, and tolerability in patients with heart failure with reduced ejection fractio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• JTT-861

Snippet

Sponsor: Akros Pharma Inc. | Conditions: Chronic Heart Failure | Phase 2 | Status: ACTIVE_NOT_RECRUITING